Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Overview
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Companies Involved in Therapeutics Development
4SC AG
KYAN Therapeutics Inc
MEI Pharma Inc
Mirati Therapeutics Inc
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Drug Profiles
Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
Product Description
Mechanism Of Action
KYAN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC-1568 - Drug Profile
Product Description
Mechanism Of Action
History of Events
mocetinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
pracinostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
resminostat - Drug Profile
Product Description
Mechanism Of Action
History of Events
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Dormant Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Discontinued Products
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Product Development Milestones
Featured News & Press Releases
Jul 03, 2020: Helsinn and MEI stop Phase III trial of pracinostat in AML
May 13, 2020: Helsinn and MEI Pharma announce updated clinical data from the phase 2 study evaluating pracinostat in combition with azacitidine in patients with high/very-high risk myelodysplastic syndromes
Feb 14, 2019: Helsinn and MEI Pharma announce publication of phase II data for Pracinostat in combition with Azacitidine in the frontline treatment of older AML patients unfit for intensive chemotherapy, in Blood Advance
Jan 28, 2019: 4SC’s pivotal RESMAIN study of resminostat in CTCL receives second positive safety review
Dec 03, 2018: Phase 2 Interim Data Evaluating the Combition of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
Nov 20, 2018: 4SC reaches significant milestone with enrollment of 100 patients in pivotal RESMAIN study of resminostat as CTCL maintence therapy
Nov 09, 2018: Mirati presents data from ongoing phase 2 clinical trial of Mocetinostat in combition with Durvalumab at the SITC 33rd Annual Meeting
Nov 05, 2018: Mirati to present new data from ongoing phase 2 clinical trial on mocetinostat and durvalumab at the SITC 33rd Annual Meeting
Nov 01, 2018: MEI Pharma to present data from Phase 2 trial of Pracinostat at ASH 2018
Jun 28, 2018: New data supports resminostat’s mechanism of action in CTCL maintence therapy
May 31, 2018: MEI Pharma and Helsinn Group Announce Successful Interim Alysis of Pracinostat/Azacitidine Phase 2 Combition Study in Higher Risk Myelodysplastic Syndrome (MDS) Patients
May 30, 2018: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combition with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f
Apr 19, 2018: Phase II study of 4SC’s resminostat in biliary tract cancer in Japan is initiated
Apr 11, 2018: Yakult Honsha recruits first Japanese patient in 4SC’s pivotal RESMAIN study of resminostat in CTCL
Mar 27, 2018: Yakult Honsha joins 4SC’s pivotal RESMAIN study of resminostat in CTCL - 4SC receives milestone payment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by 4SC AG, 2022
Pipeline by KYAN Therapeutics Inc, 2022
Pipeline by MEI Pharma Inc, 2022
Pipeline by Mirati Therapeutics Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022